FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL												
OMB Number:			3235-028									

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1/h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OND ALL KOVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person* Dietz Thomas John						2. Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [EIGR]									tionship of Reportino all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O EIGER BIOPHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 04/23/2019									belov		below	
2155 PARK BOULEVARD (Street) PALO ALTO CA 94306					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Si		Zip)															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/					tion	on 2A. Deemed Execution Date,		3. Transaction Code (Instr.		es Acquired (A) or of (D) (Instr. 3, 4 ar		5. Am Secur Benef Owne Repor Trans		ount of ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock 04/23/20)19			P		5,000	A	\$11.0)99(1)	2	20,000	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	rative rity . 3) Date (Month/Day/Year) Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transa Code (8)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		•		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$11.085 to \$11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

Remarks:

/s/ Sriram Ryali, Attorney-in-

04/23/2019

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.